<DOC>
	<DOCNO>NCT00919295</DOCNO>
	<brief_summary>This study aim investigate anti-nociceptive biogenic amine ( serotonin [ 5-hydroxytryptamine ; 5-HT ] , norepinephrine [ NE ] , dopamine [ DA ] , metabolite ) status , serum level cytokine , BDNF BH4 Thai fibromyalgia syndrome ( FMS ) patient compare representative Thai population . The efficacy tolerability mirtazapine monotherapy FMS also assess . In addition , proof concept indoleamine 2,3-dioxygenase ( IDO ) activity FMS conduct . The study divide three part . In part I , FMS patient Thai ethnicity examine determine blood and/or urinary level anti-nociceptive biogenic amine , cytokine , BDNF BH4 comparison demographically match , unrelated , healthy normal control ( HNC ) . In part II , FMS subject part I study randomize blinded therapy mirtazapine identical appear placebo . There three treatment group ( N=1:1:1 ) accommodate two dosage mirtazapine ( 15 mg , 30mg ) placebo give bedtime . Pill count baseline follow-up visit document compliance . Standard outcome instrument ( translate validate Thai language ) use baseline follow-up visit . The co-primary outcome variable change pain visual analog scale ( PVAS ) score pain responder ( &gt; = 30 % PVAS reduction ) . Secondary clinical outcome variable interest include depression , insomnia , anxiety , physical function , morning stiffness , patient global assessment disease status , patient global impression change , fibromyalgia impact questionnaire ( FIQ , quality life adverse experience . The change biogenic amine IGF-1 concentration blood and/or urine treatment examine secondary biochemical measure . In part III , IDO activity depress FMS , non-depressed FMS HNC compare . Moreover , effect mirtazapine treatment IDO activity depress non-depressed FMS patient assess . Study hypothesis 1 . Anti-nociceptive biogenic amine level Thai FMS patient low Thai healthy normal control . 2 . Higher IDO activity could observe FMS patient . 3 . Higher cytokine could observe FMS patient . 4 . Higher BDNF could observe FMS patient . 5 . Lower BH4 could observe FMS patient . 6 . Mirtazapine effective FMS treatment .</brief_summary>
	<brief_title>Study Indoleamine 2,3-dioxygenase Activity , Serum Levels Cytokines , BDNF , BH4 Mirtazapine Efficacy Fibromyalgia Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Fibromyalgia</mesh_term>
	<mesh_term>Myofascial Pain Syndromes</mesh_term>
	<mesh_term>Mirtazapine</mesh_term>
	<mesh_term>Mianserin</mesh_term>
	<criteria>Inclusion Criteria randomize control trial : male female outpatient &gt; 18 year age , descend Thai parent meet criterion FMS define American College Rheumatology 1990 score &gt; 4 pain visual analog scale ( PVAS ) score screen severe unstable physical psychiatric disorder inflammation injury trauma previous month substance abuse within past year serious suicide risk pregnancy breastfeed subject allergic reaction mirtazapine constituent severe allergic reaction multiple medication comorbid inflammatory rheumatic disease Use medication herbal agent CNS activity regular use analgesic exception acetaminophen 2 gram/day chronic use sedatives/hypnotics unable discontinue medication may affect study result ( antidepressant , mood stabilizer , antipsychotic , sleep aid hypnotic , tranquilizer , sedate antihistamine benzodiazepine , analgesic include anticonvulsant , muscle relaxant , stimulant medication dextroamphetamine methylphenidate , medication take subject treatment fibromyalgia unable attend followup schedule study agree avoidance stable maintenance unconventionalor alternative therapy , Thai traditional massage</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Fibromyalgia syndrome</keyword>
	<keyword>mirtazapine</keyword>
	<keyword>randomize control trial</keyword>
	<keyword>pilot study</keyword>
</DOC>